Pharmaceuticals

Shouyao Holdings

Shouyao Holdings released FY2026 Q1 earnings on April 17 After-Market (BJT), actual revenue CNY 28 M, actual EPS CNY 0

Shouyao Holdings FY2026 Q1 Earnings Release on April 18 After-Market (BJT)

Shouyao Holdings to Release FY2025 Annual Earnings on March 14 During-Market (BJT), Forecast Revenue CNY 28M, EPS CNY -1.51

Shouyao Holdings released FY2025 earnings on January 30 During-Market (BJT), actual revenue CNY 8.668 M (forecast CNY 28 M), actual EPS CNY -0.87 (forecast CNY -1.51)

Shouyao Holdings released FY2025 Q4 earnings during market hours on January 30, 2026 (BJT), with actual revenue of CNY 6.668 M and actual EPS of CNY 0.1777

Shouyao Holdings released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 0, actual EPS CNY -0.3399

Shouyao Holdings released FY2025 9 Months earnings on October 30 After-Market (BJT), actual revenue CNY 2M, actual EPS CNY -1.0399

Shouyao Holdings to Release FY2025 Q3 Earnings on October 31 After-Market (BJT)

Shouyao Holdings released FY2025 Q2 earnings on August 27 Pre-Market (BJT), actual revenue CNY 0, actual EPS CNY -0.36

Shouyao Holdings released FY2025 Semi-Annual Earnings on August 27 Pre-Market (BJT), actual revenue CNY 2 M, actual EPS CNY -0.7

Shouyao Holdings to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

Shouyao Holding's Second and Third Generation ALK-TKI Drugs Development Progress Smoothly

Siyao Holdings' SY-5007 Phase III Clinical Trial Results Exceed Expectations

Shouyao Holdings Obtained a Patent Authorization for 'Boronic Acid Derivatives'

Shouyao Holding-U Granted Approval for KRAS Inhibitor Combination Clinical Trial

Shouyao Holding Plans to Build a New Drug R&D and Industrialization Base

Shouyao Holding Announces 2024 Annual Report: Main Business Revenue and Net Profit Declining

Siyao Holding Announces Q1 Revenue of 200 Ten Thousand Yuan and Net Loss of 50.75 Million Yuan

Shouyao Holdings released FY2025 Q1 earnings on April 27 After-Market BJT, actual revenue CNY 2 M, actual EPS CNY -0.34

Shouyao Holdings to Release FY2025 Q1 Earnings on April 28 After-Market BJT

688197

Shouyao Holdings announced that its self-developed RET inhibitor Sotorasib tablets (SY-5007) have been accepted for new drug application by the National Medical Products Administration. This drug is suitable for patients with locally advanced or metastatic non-small cell lung cancer with RET gene fusion positivity, showing significant efficacy and good safety, and is expected to provide new treatment options for patients

Zhitong

Shouyao Holdings: RET inhibitor Sotorasib tablets (SY-5007) new drug application has been accepted

300860

603383

600009

600426

600850

On September 23, a total of 6 listed companies had their restricted shares unlocked, with a total market value of approximately 6.569 billion yuan. The specific situation of the restricted shares unlocked today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Shares Shanghai Airport 600009 Additional Issuance A Shares Original Shareholders' Allocation Listed 12.8 million HUALU-HENGSHENG 600426 Equity Incentive Restricted Circulation 280,000 CETC Digital 600850 Additional Issuance A Shares Legal Person Allocation Listed 81.107 million Apex 603383 Equity Incentive Restricted Circulation 162,000 Funshine Culture 300860 Equity Incentive Restricted Circulation 19,900 Shouyao Holdings 688197 6,491.6 million

Funshine Culture

Apex

HUALU-HENGSHENG

CETC Digital

Zhitong A-share lock-up release overview | September 23

Shouyao Holdings announced that the operating income in the first half of 2025 is 2 million yuan, a year-on-year decrease of 47.37%. The net profit attributable to shareholders of the listed company is -104 million yuan, compared to -103 million yuan in the same period last year. The proportion of R&D investment to operating income is 5,408.49%, an increase of 2,590.03 percentage points

Shouyao Holdings: Net profit loss of 104 million yuan in the first half of 2025

002653

000001

002670

399001

Today, the three major A-share indices performed strongly, with the SSE Index rising 0.6% to 3686 points, the Shenzhen Index rising 1.5% to 11518 points, and the ChiNext Index rising 2.8% to 2476 points. Brokerage stocks and innovative drug concept stocks performed prominently, with Guosheng Finance hitting the daily limit, and Shouyao Holdings and Haisco also reaching the daily limit. The central parity rate of the RMB against the USD was adjusted to 7.1350. The performance of domestic bank stocks was poor, with China Construction Bank and Industrial and Commercial Bank of China slightly declining

AASTOCKS

Haisco

SSE Index

GUOSHENG SECURITIES

Shenzhen Index

The three major A-share indices of the Shanghai and Shenzhen markets rose by 0.6% to 2.8% in the first half of the day, with brokerage and innovative drug concept stocks gaining

300468

300950

002365

001287

605500

Multiple high-priced stocks experienced adjustments today, with Forest Packaging and Forms Syntron dropping over 8%, DORIGHT and YONGAN PHARMACEUTICAL falling over 7%, and CECport and Shouyao Holdings among several stocks declining over 5%

Forms Syntron

DORIGHT

YONGAN PHARMACEUTICAL

CECport

Forest Packaging

Multiple high-priced stocks experienced adjustments today, with Forest Packaging and Forms Syntron dropping over 8%

603590

300255

Innovative drug concept stocks continue to be strong, Konruns hits the daily limit, CSBIO and Boteng Co., Ltd. rise over 10%, Lianhuan Pharmaceutical, Shouyao Holdings, and Guangshengtang all surge

Konruns

CSBIO

Innovative drug concept stocks continue to be strong, Konruns hits the limit up

688068

688331

09995

688656

300723

The innovative drug concept surged and then fell during the session, with Hob Biotech dropping over 10%, RemeGen, ApicHope, Shouyao Holdings, Hotgen, and Norland all falling over 5%

Hotgen

RemeGen

REMEGEN

Hob Biotech

ApicHope

The concept of innovative drugs surged and then fell back, with Hob Biotech dropping over 10%

Shouyao Holdings plans to invest no more than 787 million yuan to build a new drug research and development and industrialization base project in the Yizhuang New City International Pharmaceutical Innovation Park, and has signed an economic development cooperation agreement with the Beijing Economic and Technological Development Zone Management Committee. The project includes a research and development center, quality control center, clinical trial center, sales center, and production base, with a construction period of 3 years

Shouyao Holdings: Plans to invest no more than 787 million yuan to build a new drug research and development and industrialization base project

According to the Zhitong Finance APP, Shouyao Holdings released its Q1 2025 report, stating that the company's Q1 operating revenue was 2 million yuan; the net loss attributable to shareholders of the listed company was 50.751 million yuan, a year-on-year reduction in losses; the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 55.9996 million yuan, a year-on-year reduction in losses; the basic loss per share was 0.34 yuan/share

Shouyao Holdings released its first-quarter performance, with a net loss attributable to the parent company of 50.751 million yuan, narrowing the loss

Shouyao Holdings(688197.SH)